KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia

Leukemia

Volumn 24, Issue 5, 2010, Pages 1052-1055

  Medves, S ^a   Duhoux, F P ^b   Ferrant, A ^b   Toffalini, F ^a   Ameye, G ^b   Libouton, J M ^b   Poirel, H A ^b   Demoulin, J B ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; JANUS KINASE 2; PHENYLALANINE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KANK1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VALINE;

AGED; BONE MARROW BIOPSY; BONE MARROW TUMOR; CASE REPORT; CHROMOSOME 9P; CHROMOSOME TRANSLOCATION 5; CLINICAL FEATURE; DISEASE SEVERITY; EOSINOPHILIA; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DISRUPTION; GENE LOCUS; HUMAN; HUMAN TISSUE; KARYOTYPING; LETTER; LOW DRUG DOSE; MALE; MUTATIONAL ANALYSIS; NEUTROPHILIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TRANSIENT ISCHEMIC ATTACK; TUMOR SUPPRESSOR GENE;

EID: 77952429900     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.13     Document Type: Letter

References (8)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myelopro-liferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004; 61: 2912-2923.
3. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61-64.
4. Curtis CE, Grand FH, Waghorn K, Sahoo TP, George J, Cross NC. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia 2007; 21: 1839-1841.
5. Kakinuma N, Zhu Y, Wang Y, Roy BC, Kiyama R. Kank proteins: structure, functions and diseases. Cell Mol Life Sci 2009; 66: 2651-2659.
6. Yang Y, Yuzawa S, Schlessinger J. Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci USA 2008; 105: 7681-7686.
7. Lerer I, Sagi M, Meiner V, Cohen T, Zlotogora J, Abeliovich D. Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy. Hum Mol Genet 2005; 14: 3911-3920.
8. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106: 3374-3376.